TP53 and acute myeloid leukemia: Despite initial promise, a recent randomized phase 3 (ENHANCE-2) trial, the combination of magrolimab plus azacitidine failed to show clinical benefit over venetoclax plus azacitidine or 7 + 3 chemotherapy in untreated TP53- mutant AML (NCT04778397).